NCT04889794 GPS Project Evaluation of the Impact of the Reorganization of Work Into a Family Medicine Group on Pharmacotherapy and Support for the Autonomy of Seniors With Major Neurocognitive Disorders
| NCT ID | NCT04889794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | CHU de Quebec-Universite Laval |
| Condition | Major Neurocognitive Disorder |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2021-09-27 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2021-09-27 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The model of care tested in the GPS project aims to optimize pharmacotherapy for seniors undergoing cognitive assessment or suffering from major neurocognitive disorder (MCND) at home. The goal is to reduce polymedication, inappropriate medications and the treatment burden of seniors and to maintain their cognitive health, quality of life and autonomy. The intervention will include knowledge exchange sessions with nurses, pharmacists, and doctors in FMGs, and increased collaboration between these professionals and home care services teams. Other goal is to increase the satisfaction of the seniors, their families, and the professionals involved in the GPS project.
Eligibility Criteria
Inclusion Criteria: * All seniors (65 years of age or older) undergoing cognitive evaluation OR referred to a memory clinic OR having been diagnosed with cognitive impairment within the last year OR with MCND and followed up at home AND, * referred to the pharmacist, for the FMGs exposed * taking prescription medications Exclusion Criteria: * Seniors in palliative care OR * unable to answer questionnaires in French AND without a caregiver.
Contact & Investigator
Line Guénette, Ph.D
STUDY DIRECTOR
CHU de Québec-Université Laval, Laval University
Frequently Asked Questions
Who can join the NCT04889794 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Major Neurocognitive Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04889794 currently recruiting?
Yes, NCT04889794 is actively recruiting participants. Contact the research team at line.guenette@pha.ulaval.ca for enrollment information.
Where is the NCT04889794 trial being conducted?
This trial is being conducted at Montreal, Canada, Saint-Georges, Canada.
Who is sponsoring the NCT04889794 clinical trial?
NCT04889794 is sponsored by CHU de Quebec-Universite Laval. The principal investigator is Line Guénette, Ph.D at CHU de Québec-Université Laval, Laval University. The trial plans to enroll 400 participants.